Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation
- 19 March 1994
- journal article
- Published by Elsevier BV in The Lancet
- Vol. 343 (8899), 696-700
- https://doi.org/10.1016/s0140-6736(94)91579-2
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- A controlled trial of recombinant human granulocyte-macrophage colony- stimulating factor after total body irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphomaBlood, 1992
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992
- Peripheral Blood Stem Cell Mobilization by Chemotherapy With and Without Recombinant Human Granulocyte Colony-Stimulating FactorJournal of Hematotherapy, 1992
- Recombinant Granulocyte-Macrophage Colony-Stimulating Factor after Autologous Bone Marrow Transplantation for Lymphoid CancerNew England Journal of Medicine, 1991
- Bone marrow transplantation in hematologic malignancies.Current statusCancer, 1990
- Recombinant human granulocyte colony-stimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin's disease.Journal of Clinical Oncology, 1989
- GRANULOCYTE COLONY-STIMULATING FACTOR AND NEUTROPHIL RECOVERY AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE MARROW TRANSPLANTATIONThe Lancet, 1989